Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN A TOENJES

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1679585764
CMS profile
212229
Location
JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$104,996.78

276 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 5 of 6; records 201–250 of 276 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN A TOENJES

NPI 1679585764 · CMS profile ID 212229

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 6; records 201–250 of 276 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679585764?year=2024&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN A TOENJES, NPI 1679585764, CMS profile ID 212229. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 276 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679585764?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). STEVEN A TOENJES, NPI 1679585764, CMS profile ID 212229. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 276 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679585764?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
STEVEN A TOENJES, NPI 1679585764, CMS profile ID 212229, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 6; records 201–250 of 276 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1679585764?year=2024&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

276 matching records · $104,996.78 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 276 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 276.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Teva Pharmaceuticals USA, Inc. $27.2603/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151514489 CMS
ABBVIE INC. $19.4703/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106229731 CMS
Eisai Inc. $24.1203/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110783348 CMS
ABBVIE INC. $34.7003/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106229729 CMS
ACADIA Pharmaceuticals Inc $20.8303/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147995564 CMS
JAZZ PHARMACEUTICALS INC. $12.8503/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150226827 CMS
Celgene Corporation $22.0203/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101152171 CMS
Eisai Inc. $490.0003/14/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110783312 CMS
Eisai Inc. $124.0103/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110783314 CMS
Eisai Inc. $1,225.0003/14/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110783328 CMS
AstraZeneca Pharmaceuticals LP $22.2003/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104666105 CMS
ARGENX US, INC. $27.4603/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142127059 CMS
Novartis Pharmaceuticals Corporation $3.4203/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087440050 CMS
Otsuka America Pharmaceutical, Inc. $25.5903/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118994518 CMS
ABBVIE INC. $35.1003/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106229727 CMS
Lilly USA, LLC $25.1803/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135432375 CMS
Eisai Inc. $122.5502/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110783316 CMS
Eisai Inc. $490.0002/29/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110783334 CMS
Eisai Inc. $1,225.0002/29/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110783338 CMS
Novartis Pharmaceuticals Corporation $17.6002/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087440048 CMS
ABBVIE INC. $2.0202/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106229725 CMS
UCB, Inc. $19.3902/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143457809 CMS
ABBVIE INC. $16.9402/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106229723 CMS
Eisai Inc. $6,040.0002/27/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110783370 CMS
Eisai Inc. $490.0002/26/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110783324 CMS
Eisai Inc. $1,225.0002/26/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110783336 CMS
JAZZ PHARMACEUTICALS INC. $30.6202/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150226833 CMS
ABBVIE INC. $20.5502/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106229721 CMS
JAZZ PHARMACEUTICALS INC. $23.1302/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150226831 CMS
ABBVIE INC. $9.2202/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106229719 CMS
GE HEALTHCARE $18.0702/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144680999 CMS
ABBVIE INC. $3,281.2502/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106229717 CMS
Eisai Inc. $58.0002/15/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110783390 CMS
Teva Pharmaceuticals USA, Inc. $0.9302/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151514463 CMS
Teva Pharmaceuticals USA, Inc. $3.4102/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151514465 CMS
Teva Pharmaceuticals USA, Inc. $22.8802/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151514467 CMS
ABBVIE INC. $30.2202/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106229715 CMS
Eisai Inc. $11.6402/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110783374 CMS
Eisai Inc. $50.0002/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110783380 CMS
Eisai Inc. $11.6402/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110783384 CMS
Eisai Inc. $46.5802/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110783386 CMS
Eisai Inc. $40.1102/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110783388 CMS
EMD Serono, Inc. $45.9602/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120230680 CMS
Eisai Inc. $788.9002/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110783376 CMS
Eisai Inc. $249.3202/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110783378 CMS
Eisai Inc. $116.4402/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110783382 CMS
Lundbeck LLC $55.3102/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145975681 CMS
ABBVIE INC. $15.1002/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106229713 CMS
AstraZeneca Pharmaceuticals LP $16.0302/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104348086 CMS
ABBVIE INC. $446.2002/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106229703 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $101,818.22 235
PY2020 $136,232.37 270
PY2021 $98,818.16 314
PY2022 $88,348.43 244
PY2023 $48,241.43 245
PY2024 $104,996.78 276
PY2025 $116,211.61 223

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $952,343.17 31
PY2024 Principal investigator $1,278,888.09 10
PY2023 Recipient $3,268.99 3
PY2023 Principal investigator $2,130,424.04 15
PY2022 Recipient $3,075.00 2
PY2022 Principal investigator $1,152,383.00 8
PY2021 Recipient $10,126.59 2
PY2021 Principal investigator $561,074.11 17
PY2020 Principal investigator $53,127.07 53
PY2019 Principal investigator $71,597.00 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,303.40 12/27/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228736543
Principal investigator 1 PFIZER INC. $123.20 12/19/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228745673
Principal investigator 1 PFIZER INC. $2,917.60 12/17/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228736663
Principal investigator 1 Merz Pharmaceuticals, LLC $2,000.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647334
Principal investigator 1 Merz Pharmaceuticals, LLC $1,750.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647336
Principal investigator 1 Merz Pharmaceuticals, LLC $19,000.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647338
Principal investigator 1 Merz Pharmaceuticals, LLC $19,000.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647340
Principal investigator 1 Merz Pharmaceuticals, LLC $1,750.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647342
Principal investigator 1 Merz Pharmaceuticals, LLC $250.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647344
Principal investigator 1 Merz Pharmaceuticals, LLC $250.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647346
Principal investigator 1 Merz Pharmaceuticals, LLC $2,000.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647348
Principal investigator 1 PFIZER INC. $1,328.00 11/07/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228728051
Principal investigator 1 PFIZER INC. $2,869.68 11/04/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228738617
Principal investigator 1 PFIZER INC. $1,376.20 11/01/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228726995
Principal investigator 1 PFIZER INC. $3,082.80 10/21/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228741661
Principal investigator 1 PFIZER INC. $6,980.40 09/09/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228761503
Principal investigator 1 PFIZER INC. $50.40 08/29/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228767996
Principal investigator 1 PFIZER INC. $4,849.70 08/05/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228751373
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,622.64 07/28/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) No dispute reported 06/30/2026 1235996507
Principal investigator 1 PFIZER INC. $5,657.40 07/25/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228764656
Principal investigator 1 PFIZER INC. $6,256.96 07/18/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228763875
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $42,600.53 07/14/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) No dispute reported 06/30/2026 1235996505
Principal investigator 1 PFIZER INC. $17,250.00 07/02/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228765241
Principal investigator 1 Eli Lilly and Company $6.72 05/16/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187881638
Principal investigator 1 Eli Lilly and Company $903.50 04/23/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187886012
Principal investigator 1 Eli Lilly and Company $310,793.00 02/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187884776
Principal investigator 1 Eli Lilly and Company $8,559.29 02/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885372
Principal investigator 1 Eli Lilly and Company $895.75 01/27/2025 Non-covered Recipient Entity
ENCORE BORLAND-GROOVER CLINICAL
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187883332
Principal investigator 1 Eli Lilly and Company $80,752.00 01/21/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187881006
Principal investigator 1 Eli Lilly and Company $301,928.00 01/21/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187885010
Principal investigator 1 Eli Lilly and Company $104,236.00 01/21/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187885214